Senior Translational Medicine Expert, Boehringer Ingelheim
2019년 10월 10-11일
Registration from 8am
London Heathrow Marriott Hotel
Liquid Biopsies Congress 2019
- 액체생검 컨퍼런스 -
일정 : 2019년 10월 10-11일
개최: 영국, 런던, London Heathrow Marriott Hotel
정량 PCR(qPCR), 디지털 PCR, 차세대 시퀀싱(NGS) 등의 기술을 이용하여 액체생검의 개발을 가속시키고 암의 주요 비침습적 진단 검사로 발전시키기 위한 방안에 대해 파악할 수 있습니다. 이번 컨퍼런스에서는 무세포 DNA(cfDNA), 혈중 순환종양세포(CTC), 세포외소포(EV) 등의 혈중 바이오마커에 초점을 맞춥니다.
“I met leading companies/biomarker developers at one place sharing cutting edge technologies”.
“Interesting mixture of topics; possibility to discuss with the attendees”
“Learned a lot from some of the talks”
2019년 10월 10일(목) – 액체생검：방법과 기술
기조 강연: 암의 범용 바이오마커에 관한 연구 현황
MATT TRAU, Professor of Chemistry, Deputy Director and Co-Founder of AIBN, University of Queensland, Australia
Epigenetic reprogramming in cancer genomes creates a distinct methylation landscape encompassing clustered methylation at regulatory regions separated by large intergenic tracks of hypomethylated regions. This methylation landscape that we referred to as Methylscape is displayed by most cancer types, thus may serve as a universal cancer biomarker. We examine the effect of levels and genomic distribution of methylcytosines on the physicochemical properties of DNA to detect the Methylscape biomarker. We find that DNA polymeric behaviour is strongly affected by differential patterning of methylcytosine, leading to fundamental differences in DNA solvation and DNA-gold affinity between cancerous and normal genomes. We exploit these Methylscape differences to develop simple, highly sensitive and selective electrochemical or colorimetric one-step assays for the detection of cancer. These assays are quick, i.e., analysis time≤10minutes, and require minimal sample preparation and small DNA input from either solid or liquid biopsies.
기조 강연: 암 및 기타 질환에서 액체생검의 실현
SIMON LUCAS, Innovation Field Explorer, Merck KGaA
The early detection of life-threatening conditions as well as the selection of individualized treatment options for affected patients will have significant potential to disrupt our current public health sectors. Recently, alternatives to traditional tissue biopsy, such as liquid or breath biopsy, have emerged as attractive tools for the detection and management of various diseases and especially in the therapeutic area of oncology. While cancer detection with liquid biopsy is gaining acceptance, other indications often still lack a non-invasive diagnostic test, even though precision medicine is viewed as an important concept in indications outside oncology. This talk highlights the opportunities of liquid biopsy in cancer and beyond as well as our efforts at Merck to address challenges in the field with new enabling technologies.
Morning Refreshments / Poster Presentations / One-to-One Meetings
Considerations when analyzing cell-free tumor DNA
ANDERS STAHLBERG, Associate Professor, University of Gothenburg, Sweden
• Analysis of circulating cell-free tumor DNA (ctDNA) in liquid biopsies offers new means for early cancer diagnostics, real-time monitoring of treatment efficiency and detection of relapse. Despite its potential use ctDNA remains challenging to detect and to quantify as it represents only a small fraction of all cell-free DNA.
• We have developed SiMSen-Seq, that allows allele frequencies < 0.1% to be detected. SiMSen-Seq is simple to perform, flexible in multiplexing and requires minimal DNA input.
• Here, we discuss important considerations for ctDNA analysis in plasma, including all experimental steps from sampling to data interpretation. Furthermore, the use of quality control assays enables the development of robust and standardized workflows that facilitate the implementation of ctDNA analysis into clinical routine.
Standardized analysis of extracellcular vesicles in liquid biopsies
AN HENDRIX, Assistant Professor, University of Ghent, Belgium
The identification of extracellular vesicle (EV)-associated biomarkers is challenging owing to the complexity of liquid biopsies. We 1) performed quality control studies to identify the impact of (pre-) analytical variables on biomarker identification, 2) developed reference materials to ensure standardized EV measurements, and 3) created EV-TRACK to stimulate researchers to put experimental guidelines into practice. This combined expertise boosted the identification of bacterial EV in the systemic circulation of patients with intestinal barrier dysfunction.
Innovation in Research: From Protein Array to Companion Diagnostics to Profiling of Adverse Events
DOLORES CAHILL, Professor of Translational Science, University College Dublin, Ireland
Overview of profiling the autoantibody repertoire on high content protein arrays and using this approach to identify biomarkers, and develop diagnostics and companion diagnostics.
Clinical utility of CTC and ctDNA in metastatic and neo/adjuvant setting of breast cancer
JEAN-YVES PIERGA, Institut Curie, Department of Medical Oncology and Circulating Tumor Biomarkers Laboratory, SiRIC, Universite Paris Descartes, France
Circulating tumor cells (CTCs) have been identified as potential blood-based biomarker capable of providing prognostic and predictive information in breast cancer. Their applications include early diagnosis, prognostic assessment, detection of minimal residual disease, early detection of cancer relapse and management of metastatic disease. The clinical validity of the CTCbased liquid biopsy has been already assessed by numerous studies. Pooled analysis of large clinical data set in adjuvant, neoadjuvant and metastatic setting are now available. Recent results of clinical trial could support their clinical utility. The potential applications for circulating tumour DNA (ctDNA) in early and metastatic setting include prognosis assessment before treatment initiation, early assessment of treatment efficacy and help to guide personalized therapies.
ROBERT NEELY (Reserved), Associate Director, Pharmacodiagnostics, BMS
Afternoon Refreshments / Poster Presentations / One-to-One Meetings
Translating liquid biopsies into routine care
PANEL DISCUSSION – Speakers include:
Commercial Partnerships Manager, Genomics England, UK
Innovation Lead - Precision Medicine, Innovate UK
Assistant Professor, Molecular Biologist, Institut de Cancerologie de Lorraine, France
Senior Scientist, AstraZeneca, UK
Head Cellular and Molecular Diagnostics, Division Personalized Tumor Therapy, Fraunhofer-Institute for
Toxicology and Experimental Medicine ITEM-R, Germany
Innovation Field Explorer, Merck KGaA, Germany
Networking Drinks Reception
2019년 10월 11일(금) - 임상 응용
기조 강연: 암 검출을 위한 액체생검 검사
DIANA ANDERSON, Established Chair, Biomedical Sciences, University of Bradford, UK
There appeared to be no single test to identify cancer in general, but we have developed such an assay. In this modified patented Comet assay, we investigated peripheral lymphocytes from blood of 208 individuals, known as the Lymphocyte Genome Sensitivity (LGS) test. Ninety four individuals were controls. All cancers tested exhibited comparable responses. Analyses of Receiver Operating Characteristic (ROC) curves, of mean log Olive tail moments for cancer alone versus controls alone, the area under the curve was 0.93. By varying the threshold for test positivity, its sensitivity or specificity can approach 100% whilst maintaining acceptable
complementary measures. Since lymphocytes in blood only are examined, and the test has been repeated with over 900 individuals with equally valid responses, this is a useful Liquid Biopsy assay.
Liquid biopsies on the road to clinical utility
RALPH GRAESER, Senior Translational Medicine Expert, Boehringer Ingelheim
• Use of liquid biopsies in the clinic: diagnostic, prognostic, predictive?
• CTCs vs ctDNA: one or the other - or both?
• CANCER-id - a public-private partnership with the goal to standardize liquid biopsy protocols for clinical use
Morning Refreshments / Poster Presentations / One-to-One Meetings
Novel digital PCR and mutation enrichment technologies for the analysis of clinically relevant DNA alterations in liquid biopsies
MIKE MAKRIGIORGOS, Professor of Radiation Oncology, Dana Farber Cancer Institute and Harvard Medical School, USA
With the increasing interest in treatment assessment using liquid biopsy and circulating DNA, sensitive and multiplexed detection of tumor-derived alterations in blood are desirable. We provide novel forms of digital PCR, as well as mutation enrichment-based real time PCR methods that (a) enable several orders of magnitude improvement of detecting mutations or microsatellite instability than currently possible; (b) are highly multiplex-able; (c) reduce cost of analysis. Application in circulating DNA from clinical cancer samples will be presented.
A targeted multi-analyte liquid biopsy to identify early stage gynecologic cancers
JOHN MARTIGNETTIProfessor, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, and Director, Laboratory of Translational Research, Western Connecticut Health Network, USA
Overwhelmingly the power and success of “liquid biopsy” has been focused on issues related to advanced disease in already diagnosed patients under active treatment. We demonstrate an approach and the feasibility of using a targeted liquid biopsy approach for detecting early stage gynecologic cancers by combining analysis of both DNA and proteins.
CTC analysis: Latest advancements and clinical applications
EVI LIANIDOU, Professor of Analytical Chemistry - Clinical Chemistry, University of Athens, Greece
• Liquid biopsy provides a valuable source of biomarkers through simple and minimally invasive serial blood draws and represents a highly dynamic diagnostic, prognostic and theranostic tool for the management of cancer patients.
• Circulating tumor cells (CTCs) are major players in liquid biopsy and their molecular characterization offers
an exciting approach to monitor the efficacy of systemic therapies in real-time, unravel the biology of cancer cell dissemination, understand resistance to established therapies and identify gene targets and signalling pathways relevant to therapeutic interventions.
• Single-cell CTC analysis is a powerful tool to understand tumor heterogeneity and the mechanisms involved in cancer progression with potential implications for improving treatment strategies.
• This lecture will be focused on the latest developments in the detection and molecular characterization of CTCs, and their clinical applications in many types of cancer.
Prognostic and predictive value of circulating methylated DNA in metastatic colorectal cancer patients treated with regorafenib
LUDOVIC BARAULT, Senior Research Associate, Candiola Cancer Institute and the University of Torino, Italy
• Regorafenib is associated with improved progression free survival (PFS) in a subset of metastatic colorectal cancer
(mCRC) patients and no biomarkers of efficacy are available for this drug which is often associated with many toxicities.
• We previously found an association between circulating methylated DNA and outcome in chemotherapy treated mCRC patients and we hypothesized that such biomarker could be used to identify cases most likely to benefit from regorafenib (i.e. patients with PFS longer than 4 months).
• Assessment of pre and on treatment blood samples confirmed the prognostic value of circulating methylated DNA and suggest its use as biomarker for regorafenib since it may predict unresponsiveness to the treatment.
ANDREAS HAUSER, Staff Scientist, LMU, Germany
Chair’s Closing Remarks / Conference Close
* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.
London Heathrow Marriott Hotel
Bath Road, Harlington, Hayes, Middlesex, UB3 5AN
The London Heathrow Marriott Hotel provides a welcoming home away from home for business and leisure guests and is conveniently located half a mile from the airport. Stretch out in one of our beautiful guest rooms, which boast soundproof windows, pillowtop bedding and high-speed Internet access. Treat yourself to delicious dining at one of our several hotel restaurants and bars, including Tuscany Ristorante, Cast Iron Grill and THE SEVENS. Additional perks include on-site parking & free Wi-Fi in the lobby and public areas of the hotel. Staying fit here in London is easy, thanks to our modern Leisure Club and heated indoor pool. Our award winning, interactive meeting venues provide the flexibility you need to host a truly successful event. Winners of the London Venue Awards and the European Hotel Design Awards for Best Hotel Event Space.
포스터 발표는 휴식시간 및 다른 브레이크아웃 세션과 동시에 진행됩니다. 제약회사 및 연구기관의 연구자가 작성한 포스터는 모두 컨퍼런스 사무국의 승인을 받은 후 컨퍼런스 개최 장소의 전용 구역에 게시됩니다.
컨퍼런스 폐막 후 포스터 초록을 정리한 전자서적이 참가자 전원에게 배포되며, 포스터를 .pdf 형식의 파일로 제공할 수도 있습니다.(희망자에 한함)
포스터 발표는 출자 및 고용 기회를 모색하거나 같은 생각을 가진 연구자 및 같은 테마에 대해 연구하고 있는 그룹과 연구 성과를 공유하고 싶어하는 분에게 현장에서 주목받을 수 있는 최적의 기회입니다.
포스터 발표를 진행하기 위해서는 컨퍼런스 등록이 필요합니다. 포스터를 게시할 수 있는 스페이스는 한정되어 있으며 심사를 통과한 등록자부터 선착순으로 받으므로 조기 신청을 권유합니다.
기업 소속 참가자가 포스터 발표를 진행하는 경우, 100파운드의 관리비를 청구합니다. 여기에는 포스터 발표 구역을 확보하기 위한 비용 및 디스플레이 보드 비용, 각종 안내 비용 등이 포함됩니다. 연구기관 및 비영리조직의 발표자는 무료입니다.
포스터 발표 신청 방법
전용 양식에 기입한 후 2019년 9월 20일까지 제출해주시기 바립니다. 마감기한 전이라도 스페이스 신청이 완료되면 모집을 마감하므로 조기 신청을 권유합니다. 자세한 사항은 문의해주시기 바랍니다.
또한 각종 스폰서 패키지도 마련되어 있으며, 다양한 옵션 중 예산 및 사업면의 요구에 맞는 것을 선택함으로써 큰 투자수익을 얻을 수 있습니다.
다른 방식으로 이 컨퍼런스의 스폰서 참가 및 브랜딩 활동을 검토하고 있는 분도 문의해주시기 바랍니다. 각각의 요구에 맞는 서비스를 제안해드립니다.
스폰서와 전시기업은 메인 컨퍼런스의 브레이크아웃 세션 중 설정되어 있는 20분간의 개별 미팅을 사전에 예약하여 원하는 상대와 만날 수 있습니다. 컨퍼런스에서는 Global Engage팀이 현장에 상주하며 정각에 미팅이 진행되도록 지원합니다.
메인 컨퍼런스 전후로 특정 테마에 관심을 가진 분들을 대상으로 한 반일 또는 종일 워크샵을 개최할 수 있습니다. Global Engage는 워크샵 홍보 활동을 통해 충분한 참가자를 확보할 수 있도록 지원합니다.
Global Engage의 데이터베이스를 이용하여 마케팅을 진행하거나 포스터 게시, 휴식시간 및 오찬회, 리셉션, 포스터 세션 스폰서 등을 통해 브랜드 인지도를 높일 수 있습니다. 또한 참가자에게 배포되는 랜야드 및 컨퍼런스백에 로고를 인쇄하는 등 브랜딩을 위한 추가 옵션도 마련되어 있습니다.
컨퍼런스 기간에 설치되는 전용 전시 구역에서 모든 참가자에게 기술 및 제품을 소개할 수 있습니다. 전시회장은 휴식 및 오찬회, 첫째날 저녁에 진행되는 리셉션 장소로도 이용됩니다.
자세한 사항은 (주)글로벌인포메이션으로 문의해주시기 바랍니다.
비자를 포함한 입출국 절차, 전시품 등의 통관 수속은 각 전시사의 책임으로 진행하시기 바랍니다.
전시 관련 준비(회사 소개, 회사 로고, 참가자 리스트 제출 등의 전시회사 정보 등록, 부스 장식ㆍ비품 발주, 전시품 반입출ㆍ부스 관련 서류 제출, 손해보험 등)에 관해서는 주최자로 직접 연락하시기 바랍니다.
여행(숙박, 항공권), 현지 통역, 입출국ㆍ손해보험 가입 등에 관해서는 각각의 전문업체를 안내해 드리겠습니다.